63 Cosmetic Ad Violations, and 44 of Them Read Like Drug Claims

What is the signal here?

The MFDS targeted categories that draw holiday gift demand, inspected products distributed through online shopping malls, and confirmed 308 cases of false or exaggerated advertising and illegal distribution, as multiple outlets reported on September 17. By field, that breaks down into 45 cases in quasi-drugs, 63 in cosmetics, and 200 in medical devices. In quasi-drugs, 45 cases of false or exaggerated advertising were found in items with strong holiday gift demand such as toothpaste, mouth rinses and tooth whiteners. In medical devices, the agency found 142 cases of illegal distribution advertising for products like blood pressure monitors and low-frequency stimulators, plus 58 cases of unfair advertising in which ordinary consumer goods were made to look like medical devices through phrasing such as 'pain relief.'

Separate out the cosmetics and the pattern is distinct. Of the 63 cases, 44 advertised the product as though it had efficacy comparable to a drug. The expressions cited as examples in the reporting were phrases carrying medical meaning — 'skin regeneration,' 'anti-inflammatory,' 'increases ovarian hormones,' 'cell regeneration' — and one headline carried the line 'no skin regeneration, no anti-aging' directly. Alongside those, the coverage set out that expressions naming a specific type of institution, such as 'hospital-exclusive cosmetics' or 'for dermatology procedures,' and expressions borrowing a procedure name, such as 'botox cosmetics,' are also treated as unfair advertising.

That said, these figures should not be read as a violation rate for the market as a whole. The 308 cases came from a planned inspection that selected particular product groups ahead of the holiday, not from a continuous census, and a different selection basis would produce a different count. The counts are per advertising listing rather than per brand, so one brand can appear in several cases. The specific brands or product names behind the 63 cosmetic cases are not in the published reporting. So what to take from this inspection is not who got caught, but which types of sentences keep getting caught.

1. The violations sit in the copy, not the formula

That 44 of the 63 cosmetic cases were the drug-confusion type suggests the problem arose less from the formulation or the raw materials than from how they were described. Even for the same formula, 'helps soothe the skin' and 'anti-inflammatory' sit on entirely different levels. The first speaks to the purpose and feel of a cosmetic; the second implies action on a condition.

In practice, that line blurs in two places. One is when supplier documentation for a raw material is carried over word for word. Ingredient-level test results and academic phrasing are often unsuitable as finished-product advertising copy. The other is when an influencer or a sales channel rewrites the wording on their own. Once the sentence the brand approved differs from the sentence actually displayed, an inspection catches the displayed one.

So it is safer to settle 'what we will say about it' alongside 'what we will make' during development. Phrasing that came out of a formulation meeting carries straight through to the product page more often than you would expect.

• Whether supplier wording was copied into finished-product copy as is
• Whether words carrying medical meaning — disease, treatment, regeneration, inflammation — slipped in
• Whether the wording differs across product pages, banners and video captions by channel
• Whether prohibited expressions remain in the guidance sent to external reviewers

2. Borrowing the name of an institution or a procedure is especially risky

One of the types set out in this round of reporting covers expressions that name a specific type of institution, such as 'hospital-exclusive cosmetics' or 'for dermatology procedures,' along with expressions that borrow a procedure name, such as 'botox cosmetics.' Such phrasing is a problem because, even without stating an efficacy outright, it leads consumers to expect an outcome comparable to a drug or a medical treatment.

When the MFDS revised its guidance on cosmetic labeling and advertising and expanded the list of prohibited expressions, reporting at the time listed phrases such as 'hospital-exclusive,' 'for dermatology procedures,' 'pharmacy-exclusive,' 'exosome cosmetics,' 'microneedle,' 'inner care,' and 'skin age reduced by 10 years' as wording that cannot be used. A brand working with a derma concept or an expert-endorsement framing should compare that list against its own copy directly.

Worth noting: the concept itself is not what is prohibited. Making a product that addresses concerns often raised in a dermatology consultation is one thing; calling that product 'for dermatology procedures' is another. Most cases are resolved by keeping the concept and changing the sentence.

3. Substantiation is judged by fit with the claim, not by whether a document exists

A common misconception about claim substantiation is that a test report alone licenses any sentence. In practice the evidence has to support exactly what the advertising sentence asserts, and to the same extent. If the test subjects, sample size, duration or measured endpoints are narrower than the claim, the expression is unsubstantiated even though documentation exists.

Korean industry media has cited examples of unsubstantiable expressions caught in inspections, such as 'up to 84.47% reduction in volume after two weeks of use' and '22.19% reduction in pore count.' Figures carried to two decimal places look specific enough to earn trust, but they also narrow exactly what has to be supported. The moment the word 'up to' appears, you need to be able to explain the conditions under which that maximum was obtained.

Where a human application study is run, the party conducting it and the conditions also have to meet the requirements. Multiple sources repeat that such studies must be performed and evaluated under the direction and supervision of a specialist physician or hospital in the relevant field, or of someone at a domestic or overseas university or specialized cosmetic research institute with testing experience in that field. Checking these requirements before commissioning a study saves time.

4. Holiday gift sets scatter the copy across many places

It matters that this inspection centered on items with high holiday gift demand ahead of Chuseok. Unlike a single product, a gift set does not keep its advertising copy in one place. Sentences spread across the set product page, the individual product pages for each component, the outer packaging, the enclosed leaflet, and promotional banners that differ by channel.

A familiar situation follows. The individual product pages went through review, but the copy introducing the set composition was written fresh at the marketing stage and skipped it. Seasonal volumes run on tight schedules, which makes that kind of gap easy to create.

The response is simple. Treat the set as one product, build a list of every sentence that will be displayed, and review them all against the same standard in one pass. Building the list takes far less time than rewriting after an inspection.

• The body and summary copy on the set product page
• Sentences carried over from individual component product pages
• Copy printed on outer boxes, sleeves and leaflets
• Promotional banners and search advertising copy by channel
• Collaboration content and the wording guide given to reviewers

5. Put the line between manufacturer and brand in writing

In an OEM/ODM structure, the manufacturer usually handles the formula and the testing while the brand handles the advertising copy. The problem lives in the material between them. As the brand interprets test results supplied by the manufacturer and turns them into sentences, the scope tends to widen a little at a time.

So there are items worth settling early in development: which tests will be run on this product, how far the resulting evidence can support a claim, and which side reviews the advertising copy at which point. Agree on those three verbally only, and they are the first things to come apart when the season gets busy.

In discussions with a manufacturing partner such as COSLAB, 'what evidence would we need in order to use this sentence?' is a faster question than 'can we use this sentence?' The first hands the judgment to the other side; the second surfaces the schedule and cost immediately.

The first question for the brief

Write this on the first line of the brief: what are the three core sentences for this product, and where is the evidence behind each one? That 44 of the 63 cosmetic cases in this inspection were the drug-confusion type means most of the risk is created on the product page rather than in the lab. Settle the ceiling on your claims in the same meeting where you settle the formula, and you will spend less time rewriting sentences under seasonal deadline pressure.